Thermographic evaluation of piroxicam’s effect as an adjuvant treatment in canine mammary tumors
Mammary tumors are the second most diagnosed neoplasms in dogs. Canine females are largely affected by malignant mammary tumours. Several factors are involved in the development and determination of the malignancy of these lesions, including the action of cyclooxygenase-2. Use of non-steroidal anti-...
| Authors: | , , , , , , |
|---|---|
| Format: | article |
| Status: | Published version |
| Publication Date: | 2021 |
| Country: | Brasil |
| Institution: | Universidade Federal de Itajubá (UNIFEI) |
| Repository: | Research, Society and Development |
| Language: | Portuguese |
| OAI Identifier: | oai:ojs.pkp.sfu.ca:article/12236 |
| Online Access: | https://rsdjournal.org/index.php/rsd/article/view/12236 |
| Access Level: | Open access |
| Keyword: | Perros Oncología Inflamación Glándula Mamaria Inhibidores COX-2. Canino Oncologia Glândulas Mamárias Inflamação Inibidores COX-2. Canine Oncology Inflammation Mammary Gland COX-2 Inhibitors. |
| Summary: | Mammary tumors are the second most diagnosed neoplasms in dogs. Canine females are largely affected by malignant mammary tumours. Several factors are involved in the development and determination of the malignancy of these lesions, including the action of cyclooxygenase-2. Use of non-steroidal anti-inflammatory drugs as enzyme-inhibiting drugs has been studied as a promising adjuvant treatment for neoplasms. The aim of this study was to evaluate the effect of piroxicam in reducing inflammation caused by mammary tumours in 25 bitches during 10 days of administration based on the measurement of peritumoral temperature using thermography. The results indicated a significant difference (p=0,003) between the average temperatures at the first and last day of treatment. When performing the evaluation of malignant and benign neoplasms separately, it was possible to observe that, statistically, malignant neoplasms (n=19) showed a significant reduction in peritumoral temperatures (P=<0.001), however, benign neoplasms (n=6) have not obtained a significant difference in temperature after the therapeutic protocol (P=0.954). Therefore, it was possible to demonstrate the efficacy of the medication in reducing the heat caused by inflammation and allowing advances in the development of therapeutic protocols for mammary tumors in bitches, such as the inclusion of the drug in the period prior to the mastectomy surgeries. |
|---|